Results 41 to 50 of about 54,594 (319)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer Discovery, 2022
Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tumors.
A. Schram, I. Odintsov, Madelyn Espinosa-Cotton, I. Khodos, W. J. Sisso, M. Mattar, A. Lui, M. Vojnic, Sara H Shameem, Thrusha Chauhan, J. Torrisi, J. Ford, M. O’Connor, C. Geuijen, R. Schackmann, J. J. Lammerts van Bueren, E. Wasserman, E. de Stanchina, E. O’Reilly, M. Ladanyi, A. Drilon, R. Somwar   +21 more
semanticscholar   +1 more source

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

Nature Communications
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target ...
Ming Shi, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, W. Sang, K. Qi, Depeng Li, F. Zhu, Zhenyu Li, J. Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, K. Xu, Junnian Zheng, Jiang Cao   +21 more
semanticscholar   +1 more source

Bispecific Antibodies: From Research to Clinical Application

Frontiers in Immunology, 2021
Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different antigens or two different epitopes on the same antigen. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with ...
Jiabing Ma, Yicheng Mo, Menglin Tang, Junjie Shen, Yanan Qi, Wenxu Zhao, Yi Huang, Yanmin Xu, Cheng Qian   +8 more
semanticscholar   +1 more source

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

Antibodies, 2019
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yanling Wu, Tianlei Ying   +10 more
doaj   +1 more source

Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer

Cells, 2021
Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy.
Fabrizio Marcucci, Cristiano Rumio
doaj   +1 more source

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Frontiers in Immunology
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies.
Zhijuan Ai, Bing Wang, Yunlong Song, Panpan Cheng, Xin-long Liu, Peng Sun   +5 more
semanticscholar   +1 more source

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Frontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jingbiao Wei, Yueyao Yang, Gang Wang, Ming Liu   +3 more
semanticscholar   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs

bioRxiv, 2023
The inability of antibodies and other biologics to penetrate the blood-brain barrier (BBB) is a key limitation to their use in diagnostic, imaging, and therapeutic applications.
Ghasidit Pornnoppadol, Layne G. Bond, Michael J. Lucas, J. Zupancic, Yun-Huai Kuo, Boya Zhang, C. Greineder, Peter M. Tessier   +7 more
semanticscholar   +1 more source